Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a combination of two drugs ipatasertib and
atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have
circulating tumor DNA in the blood.
This research study involves the following investigational drugs:
- Sacituzumab govitecan
- Atezolizumab